Univariate and multivariate linear regression analysis of 5-year data for all patients (n = 72), and for men and women separately.
| Variables | Total Score at 5-year Followup (age-adjusted single variable, linear regression analysis). β (95% CI). All, n = 72 | Total Score at 5-year Followup (multivariate linear regression analysis). β (95% CI). All, n = 72 | Total Score at 5-year Followup (age-adjusted single variable, linear regression analysis). β (95% CI). Male, n = 29 | Total Score at 5-year Followup (multivariate linear regression analysis). β (95% CI). Male, n = 29 | Total Score at 5-year Followup (age-adjusted single variable, linear regression analysis). β (95% CI). Female, n = 43 | Total Score at 5-year Followup (multivariate linear regression analysis). β (95% CI). Female, n = 43 |
|---|---|---|---|---|---|---|
| Age, BL | 0.031 (−0.08–0.14) p = 0.60 | 0.002 (−0.08–0.08) p = 0.26 | 0.018 (−0.31–0.34) p = 0.91 | 0.045 (−0.12–0.21) p = 0.56 | 0.058 (−0.04–0.16) p = 0.25 | 0.005 (−3.2–4.3) p = 0.76 |
| Male/female | 4.6 (0.58–8.6) p = 0. 027 | 1.3 (−1.0–3.6) p = 0.28 | NA | NA | NA | NA |
| Abnormal BL score | 7.9 (4.3–12) p < 0.001 | 11.6 (3.0–20) p = 0.01 | 6.7 (1.7–12) p = 0.01 | 5.2 (2.7–7.7) p < 0.001 | ||
| BL total score | 2.1 (1.7–2.5) p < 0.001 | 1.5 (1.1–1.8) p < 0.001 | 2.3 (1.6–3.2) p < 0.001 | 1.6 (1.3–2.0) p < 0.001 | 1.6 (1.2–2.0) p < 0.001 | |
| DAS28 BL | 1.0 (−0.67–2.7) p = 0.23 | 2.5 (−1.6– 6.7) p = 0.22 | 0.03 (−1.3–1.3) p = 0.96 | |||
| SJC BL | 0.36 (−0.15–0.88) p = 0.16 | 0.50 (−0.55–1.5) p = 0.34 | 0.12 (−0.31–0.55) p = 0.59 | |||
| TJC BL | 0.06 (−0.30–0.43) p = 0.73 | 0.23 (−0.51–0.97) p = 0.53 | −0.18 (−0.48–0.12) p = 0.24 | |||
| HAQ BL | 0.14 (−3.6–3.8) p = 0.94 | 7.4 (−5.8–20) p = 0.26 | 0.13 (−2.4–2.7) p = 0.92 | |||
| Months of delay | 0.04 (−0.30–0.38) p = 0.81 | −0.12 (−0.92–0.68) p = 0.76 | 0.07 (−0.19–0.32) p = 0.59 | |||
| Smoking at BL | 0.74 (−4.1–5.6) p = 0.76 | 7.1 (−4.9–19) p = 0.25 | −1.9 (−5.2–1.4) p = 0.26 | |||
| MTX ever before 5-yr followup | 3.5 (0.35–6.7) p = 0.03 | 0.49 (−1.8–2.8) p = 0.67 | 6.6 (1.1–12) p = 0.021 | −2.33 (−7.4–2.8) p = 0.35 | 1.7 (−2.1–5.5) p = 0.37 | −0.9 (2.9–1.1) p = 0.36 |
| Biologic ever | −1.34 (−7.2–4.5) p = 0.65 | −0.51 (−12–11) p = 0.93 | −1.4 (−8.1–5.4) p = 0.67 | |||
| Any enthesitis at BL | −2.9 (−7.4–1.5) p = 0.20 | −4.2 (−15–6.8) p = 0.44 | −1.9 (−5.1–1.4) p = 0.25 | |||
| Any tenosynovitis at BL | 5.61 (1.0–10) p = 0.016 | 0.35 (−2.1–2.8) p = 0.78 | 7.1 (−3.2–17) p = 0.17 | 3.1 (−0.67–6.8) p = 0.10 | 4.04 (0.73–7.4) p = 0.018 | 1.3 (−0.99–3.6) p = 0.25 |
| Any dactylitis at BL | 1.5(−3.0–6.0) p = 0.51 | 1.3 (−9–12) p = 0.80 | 2.04 (−1.6–5.7) p = 0.27 | |||
| Any dactylitis at 5-yr followup | 6.30 (1.5–11) p = 0.019 | 4.5 (1.9–7.5) p = 0.001 | 8.3 (−2.3–19) p = 0.12 | 9.1 (4.3–14) p = 0.001 | 3.02 (−1.3–7.3) p = 0.16 | 2.9 (0.15–5.6) p = 0.04 |
Significant p values are shown in bold face. BL: baseline; SJC: swollen joint count; TJC: tender joint count; DAS28: 28-joint Disease Activity Score; HAQ: Health Assessment Questionnaire; MTX: methotrexate; NA: not applicable.